Advaxis, Inc. (NASDAQ:ADXS) shares were up 11.3% during mid-day trading on Wednesday . The company traded as high as $0.36 and last traded at $0.28, approximately 28,310,008 shares changed hands during trading. An increase of 2,660% from the average daily volume of 1,025,552 shares. The stock had previously closed at $0.25.
A number of equities analysts recently issued reports on ADXS shares. HC Wainwright restated a “neutral” rating on shares of Advaxis in a report on Wednesday, June 12th. ValuEngine upgraded Advaxis from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, Zacks Investment Research upgraded Advaxis from a “sell” rating to a “hold” rating in a report on Friday, August 9th.
The firm has a market capitalization of $5.05 million, a PE ratio of -0.01 and a beta of 3.21. The company has a fifty day simple moving average of $0.36 and a two-hundred day simple moving average of $1.85.
Advaxis Company Profile (NASDAQ:ADXS)
Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer.
Featured Story: Is the QQQ ETF safe?
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.